Compare Amphastar Pharmaceuticals Inc (AMPH) vs Core and Main Inc (CNM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Core & Main (CNM) trades at $45.86, showing a 1.44% daily gain amid a bearish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.72 exceeding expectations. Fundamentally, the company maintains solid profitability with a 5.87% net margin and 23.73% ROE, though valuation metrics appear elevated with a P/E of 19.43. Recent news highlights the company's senior notes offering and resilient municipal demand despite residential weakness.

The outlook remains cautiously optimistic with analyst consensus favoring Buy ratings (57%), but technical indicators signal near-term pressure. Key opportunities include strong municipal business performance and margin expansion, while risks involve high debt levels and industry headwinds. The stock's current position near support at $45 suggests potential for consolidation before next earnings catalyst.